ZNF304

Summary

ZNF304 (zinc finger protein 304, HGNC:13505) is a protein-coding gene on chromosome 19q13.43, encoding Zinc finger protein 304 (Q9HCX3). Acts as a transcriptional regulator and plays a role in gene silencing.

This gene encodes a member of the Krueppel C2H2-type zinc-finger family of proteins. The encoded protein functions as a transcriptional repressor that recruits a corepressor complex to stimulate promoter hypermethylation and transcriptional silencing of target genes. Expression of this gene is upregulated in colorectal, ovarian and breast cancer, and this gene may promote cancer cell survival, growth and invasion.

Source: NCBI Gene 57343 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 99 total
• MANE Select transcript: NM_020657

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13505
Approved symbol	ZNF304
Name	zinc finger protein 304
Location	19q13.43
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000131845
Ensembl biotype	protein_coding
OMIM	613840
Entrez	57343

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000282286, ENST00000391705, ENST00000443917, ENST00000598744

RefSeq mRNA: 4 — MANE Select: NM_020657 NM_001290318, NM_001290319, NM_001329456, NM_020657

CCDS: CCDS12950, CCDS74462, CCDS77365

Canonical transcript exons

ENST00000282286 — 3 exons

Exon	Start	End
ENSE00000822478	57356030	57359898
ENSE00003488071	57353725	57353851
ENSE00003902381	57351271	57351697

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 92.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.6678 / max 47.4555, expressed in 1631 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177768	4.6678	1631

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	92.07	gold quality
oocyte	CL:0000023	84.78	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.71	gold quality
cortical plate	UBERON:0005343	82.74	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.75	gold quality
ganglionic eminence	UBERON:0004023	79.98	gold quality
cerebellar cortex	UBERON:0002129	78.37	gold quality
cerebellar hemisphere	UBERON:0002245	78.33	gold quality
stromal cell of endometrium	CL:0002255	78.29	gold quality
ventricular zone	UBERON:0003053	78.04	gold quality
cerebellum	UBERON:0002037	77.95	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.47	gold quality
adrenal tissue	UBERON:0018303	77.35	gold quality
apex of heart	UBERON:0002098	77.24	gold quality
Brodmann (1909) area 23	UBERON:0013554	77.03	gold quality
amniotic fluid	UBERON:0000173	76.93	gold quality
left adrenal gland cortex	UBERON:0035825	76.83	gold quality
heart left ventricle	UBERON:0002084	76.69	gold quality
islet of Langerhans	UBERON:0000006	76.66	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	76.59	silver quality
germinal epithelium of ovary	UBERON:0001304	76.57	gold quality
cardiac ventricle	UBERON:0002082	76.56	gold quality
left adrenal gland	UBERON:0001234	76.54	gold quality
adrenal gland	UBERON:0002369	76.47	gold quality
adrenal cortex	UBERON:0001235	76.38	gold quality
myocardium	UBERON:0002349	76.21	gold quality
biceps brachii	UBERON:0001507	75.98	gold quality
lower esophagus muscularis layer	UBERON:0035833	75.86	gold quality
lower esophagus	UBERON:0013473	75.84	gold quality
heart	UBERON:0000948	75.81	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.91

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CDKN2A	Repression
CDKN2B	Repression

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

72 targeting ZNF304, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-548A-3P	99.76	70.58	3524

Literature-anchored findings (GeneRIF, showing 3)

• Identification of ZNF304, by AU-motif-directed display method and characterization of its role in lymphocyte activation (PMID:12051768)
• transcriptional regulator of beta1 integrin, promotes cancer cell survival and protects against anoikis in ovarian cancer (PMID:26081979)
• Genome-wide CRISPR knockout screen identifies ZNF304 as a silencer of HIV transcription that promotes viral latency. (PMID:32956422)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zfx	ENSDARG00000074453
danio_rerio		ENSDARG00000098424
mus_musculus	Zfy2	ENSMUSG00000000103
mus_musculus	Zfy1	ENSMUSG00000053211
rattus_norvegicus	Zfy1	ENSRNOG00000053042

Paralogs (38): ZFX (ENSG00000005889), ZBTB11 (ENSG00000066422), ZFAT (ENSG00000066827), ZFY (ENSG00000067646), ZNF586 (ENSG00000083828), IKZF5 (ENSG00000095574), ZNF419 (ENSG00000105136), ZNF549 (ENSG00000121406), ZSCAN20 (ENSG00000121903), PRDM15 (ENSG00000141956), ZNF660 (ENSG00000144792), ZNF711 (ENSG00000147180), ZNF773 (ENSG00000152439), ZNF256 (ENSG00000152454), ZNF837 (ENSG00000152475), ZNF691 (ENSG00000164011), ZNF610 (ENSG00000167554), E4F1 (ENSG00000167967), ZNF562 (ENSG00000171466), ZNF561 (ENSG00000171469), ZNF584 (ENSG00000171574), ZIK1 (ENSG00000171649), ZNF570 (ENSG00000171827), ZSCAN2 (ENSG00000176371), ZNF552 (ENSG00000178935), ZNF154 (ENSG00000179909), ZNF792 (ENSG00000180884), ZNF793 (ENSG00000188227), ZNF548 (ENSG00000188785), ZNF79 (ENSG00000196152), ZNF418 (ENSG00000196724), ZNF772 (ENSG00000197128), ZNF583 (ENSG00000198440), ZNF480 (ENSG00000198464), ZNF551 (ENSG00000204519), ZNF134 (ENSG00000213762), ZNF587B (ENSG00000269343), ZNF8 (ENSG00000278129)

Protein

Protein identifiers

Zinc finger protein 304 — Q9HCX3 (reviewed: Q9HCX3)

Alternative names: KRAB-containing zinc finger protein

All UniProt accessions (3): E7EQD3, M0QZ59, Q9HCX3

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a transcriptional regulator and plays a role in gene silencing. Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of several tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells. Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) by inducing trimethylation of ‘Lys-27’ of histone H3 (H3K27me3) in a Polycomb group (PcG) complexes-dependent manner. Associates at promoter regions of TSGs and mediates the recruitment of the corepressor complex containing the scaffolding protein TRIM28, methyltransferase DNMT1 and histone methyltransferase SETDB1 and/or the PcG complexes at those sites. Transcription factor involved in the metastatic cascade process by inducing cell migration and proliferation and gain resistance to anoikis of ovarian carcinoma (OC) cells via integrin-mediated signaling pathways. Associates with the ITGB1 promoter and positively regulates beta-1 integrin transcription expression. Promotes angiogenesis. Promotes tumor growth.

Subunit / interactions. Probably part of a corepressor complex containing ZNF304, TRIM28, SETDB1 and DNMT1; leading to promoter hypermethylation and transcriptional silencing. Probably associates with Polycomb group (PcG) complexes; leading to trimethylation of ‘Lys-27’ of histone H3 (H3K27me3). Interacts with USP28.

Subcellular location. Nucleus.

Tissue specificity. Expressed in undifferentiated embryonic stem cells (ESCs). Expressed strongly in colorectal cancers cells (CRCs). Expressed strongly in ovarian carcinoma (OC) tumor cell lines compared to non-transformed ovarian epithelial cells (at protein level). Expressed in lymphoid tissues, thyroid, adrenal gland, prostate, pancreas and skeletal muscles.

Post-translational modifications. Deubiquitinated by USP28; the deubiquitination leads to the stabilization of ZNF304 from proteolytic degradation.

Induction. Down-regulated during embryonic stem cells (ESCs) differentiation by retinoic acid treatment.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (4): NP_001277247, NP_001277248, NP_001316385, NP_065708* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (23 total): zinc finger region 16, sequence conflict 3, sequence variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCX3-F1	65.32	0.21

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 89 (showing top): GOBP_POSITIVE_REGULATION_OF_VASCULATURE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, GOBP_DNA_METHYLATION_DEPENDENT_CONSTITUTIVE_HETEROCHROMATIN_FORMATION, GOBP_BLOOD_VESSEL_MORPHOGENESIS, GOBP_NEGATIVE_REGULATION_OF_ANOIKIS, GOBP_REGULATION_OF_ANOIKIS, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GOBP_EPITHELIAL_CELL_PROLIFERATION, GOBP_CHROMATIN_REMODELING, GOBP_HETEROCHROMATIN_ORGANIZATION, DANG_BOUND_BY_MYC, GOBP_INTEGRIN_MEDIATED_SIGNALING_PATHWAY, NOUZOVA_METHYLATED_IN_APL, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT

GO Biological Process (13): negative regulation of transcription by RNA polymerase II (GO:0000122), angiogenesis (GO:0001525), DNA methylation-dependent constitutive heterochromatin formation (GO:0006346), regulation of transcription by RNA polymerase II (GO:0006357), integrin-mediated signaling pathway (GO:0007229), positive regulation of cell migration (GO:0030335), positive regulation of angiogenesis (GO:0045766), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of epithelial cell proliferation (GO:0050679), negative regulation of anoikis (GO:2000811), chromatin organization (GO:0006325), regulation of DNA-templated transcription (GO:0006355), positive regulation of biosynthetic process (GO:0009891)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), promoter-specific chromatin binding (GO:1990841), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of DNA-templated transcription	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
constitutive heterochromatin formation	1
regulation of DNA-templated transcription	1
cell surface receptor signaling pathway	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
angiogenesis	1
regulation of angiogenesis	1
positive regulation of vasculature development	1
positive regulation of DNA-templated transcription	1
positive regulation of cell population proliferation	1
epithelial cell proliferation	1
regulation of epithelial cell proliferation	1
negative regulation of apoptotic process	1
anoikis	1
regulation of anoikis	1
cellular component organization	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
biosynthetic process	1
regulation of biosynthetic process	1
positive regulation of metabolic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
chromatin binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

484 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF304	DNMT1	P26358	790
ZNF304	TRIM28	Q13263	623
ZNF304	SETDB1	Q15047	611
ZNF304	NICN1	Q9BSH3	463
ZNF304	TMEM178A	Q8NBL3	448
ZNF304	MAFG	O15525	447
ZNF304	ZC3H4	Q9UPT8	429
ZNF304	OR8B4	Q96RC9	411
ZNF304	FBXO48	Q5FWF7	410
ZNF304	OR5AP2	Q8NGF4	379
ZNF304	BHLHA9	Q7RTU4	368
ZNF304	FTSJ3	Q8IY81	361
ZNF304	TRAT1	Q6PIZ9	360
ZNF304	FOXD4L6	Q3SYB3	358
ZNF304	OR1L8	Q8NGR8	358

IntAct

4 interactions, top by confidence:

A	B	Type	Score
MAP1LC3A	ZNF304	psi-mi:“MI:0407”(direct interaction)	0.440
ECE1	ZNF304	psi-mi:“MI:0915”(physical association)	0.370
ZNF304	IPO8	psi-mi:“MI:0914”(association)	0.350

BioGRID (6): USP28 (Affinity Capture-Western), ZNF304 (Affinity Capture-Western), ZNF304 (Affinity Capture-MS), ZNF304 (Affinity Capture-RNA), TRIM28 (Affinity Capture-Western), ZNF304 (Protein-peptide)

ESM2 similar proteins: A6NDX5, A8MQ14, B7Z6K7, C9JN71, O43361, P0CJ79, P0DKX0, P17017, P17021, P17027, P17035, P17039, P51522, Q02386, Q13106, Q14585, Q3SYV7, Q3ZCX4, Q4R4C7, Q4V348, Q52M93, Q5R9F0, Q5RB30, Q5SXM1, Q6P3V2, Q6P5C7, Q6P9A1, Q6PDB4, Q6ZN06, Q6ZN08, Q6ZN57, Q76KX8, Q7Z340, Q86V71, Q86XN6, Q8N4W9, Q8N7Q3, Q8N8Z8, Q8TC21, Q8TF45

Diamond homologs: A2RRD8, A6NFI3, A6NM28, A8MUZ8, A8MWA4, B2RUI1, B4DU55, E9Q8G5, O43296, O43361, O75467, O75820, P0CH99, P0CI00, P10078, P16373, P16374, P17021, P17023, P17032, P17097, P17098, P21506, P51786, P52740, Q06732, Q08ER8, Q13106, Q13360, Q13398, Q14592, Q147U1, Q32M78, Q3KQV3, Q3MIS6, Q3SY52, Q571J5, Q5CZA5, Q5HY98, Q5R7I8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ZNF304	“down-regulates quantity by repression”	CDKN2A	“transcriptional regulation”
ZNF304	“down-regulates quantity by repression”	CDKN2B	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

811 predictions. Top by Δscore:

Variant	Effect	Δscore
19:57351695:CAGG:C	donor_loss	1.0000
19:57353721:GCAG:G	acceptor_loss	1.0000
19:57353723:A:AG	acceptor_gain	1.0000
19:57353723:AGAGT:A	acceptor_loss	1.0000
19:57353724:G:GA	acceptor_gain	1.0000
19:57353724:GA:G	acceptor_gain	1.0000
19:57353724:GAGT:G	acceptor_gain	1.0000
19:57353724:GAGTT:G	acceptor_gain	1.0000
19:57353847:ACTAG:A	donor_gain	1.0000
19:57353848:CTAG:C	donor_gain	1.0000
19:57353848:CTAGG:C	donor_loss	1.0000
19:57353849:TAG:T	donor_gain	1.0000
19:57353849:TAGG:T	donor_loss	1.0000
19:57353850:AG:A	donor_gain	1.0000
19:57353850:AGGT:A	donor_loss	1.0000
19:57353851:GG:G	donor_gain	1.0000
19:57353851:GGTA:G	donor_loss	1.0000
19:57353852:G:GG	donor_gain	1.0000
19:57353852:GTA:G	donor_loss	1.0000
19:57353853:T:G	donor_loss	1.0000
19:57351389:G:GT	donor_gain	0.9800
19:57351693:TTC:T	donor_gain	0.9800
19:57351698:G:GG	donor_gain	0.9800
19:57353719:T:TA	acceptor_gain	0.9800
19:57353720:G:A	acceptor_gain	0.9800
19:57355189:A:T	donor_gain	0.9800
19:57351452:G:GT	donor_gain	0.9600
19:57353719:T:G	acceptor_gain	0.9300
19:57353722:CAG:C	acceptor_gain	0.9300
19:57353723:AGA:A	acceptor_gain	0.9300

AlphaMissense

4445 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:57357422:T:C	L518P	0.999
19:57357487:T:C	F540L	0.999
19:57357489:T:A	F540L	0.999
19:57357489:T:G	F540L	0.999
19:57356983:T:C	F372L	0.998
19:57356985:T:A	F372L	0.998
19:57356985:T:G	F372L	0.998
19:57357235:T:C	F456L	0.998
19:57357237:T:A	F456L	0.998
19:57357237:T:G	F456L	0.998
19:57357319:T:C	F484L	0.998
19:57357321:C:A	F484L	0.998
19:57357321:C:G	F484L	0.998
19:57357170:T:C	L434P	0.997
19:57357403:T:C	F512L	0.997
19:57357405:C:A	F512L	0.997
19:57357405:C:G	F512L	0.997
19:57357506:T:C	L546P	0.997
19:57357086:T:C	L406P	0.996
19:57357151:T:C	F428L	0.996
19:57357153:T:A	F428L	0.996
19:57357153:T:G	F428L	0.996
19:57357346:C:G	H493D	0.996
19:57357348:C:A	H493Q	0.996
19:57357348:C:G	H493Q	0.996
19:57357514:C:G	H549D	0.996
19:57356815:T:C	F316L	0.995
19:57356817:C:A	F316L	0.995
19:57356817:C:G	F316L	0.995
19:57356990:G:C	R374P	0.995

dbSNP variants (sampled 300 via entrez): RS1000221473 (19:57356148 G>A,T), RS1000872622 (19:57355472 T>C), RS1001266964 (19:57353263 T>C), RS1001340567 (19:57353627 G>A,C), RS1001797966 (19:57354384 C>G,T), RS1001891325 (19:57354719 G>C), RS1002300288 (19:57354606 G>A,T), RS1002646671 (19:57351605 G>A,C,T), RS1002918124 (19:57351392 C>T), RS1003012111 (19:57352071 C>G,T), RS1003467418 (19:57352668 T>G), RS1003764708 (19:57359937 A>G,T), RS1004310465 (19:57358211 G>A,C), RS1004340196 (19:57358303 A>G), RS1004725633 (19:57350346 T>C)

Disease associations

OMIM: gene MIM:613840 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007743_5	Iris color (L* coordinate)	9.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009764	eye colour measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
geraniol	increases expression	1
trichostatin A	affects expression	1
sodium arsenite	decreases expression	1
zinc chromate	increases abundance, increases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	increases expression	1
abrine	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Rotenone	decreases expression	1
Urethane	increases expression	1
Zinc	decreases expression	1
Aflatoxin B1	increases methylation	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer